Is Bimagrumab Approved? Status, Timeline, and the Body-Composition Thesis (2026)
No. Bimagrumab is still a Phase 2b asset. Its value is not about near-term approval. It is about whether muscle-preservation biology becomes important enough to change the obesity category.
Current stage
Phase 2b
Approval read
Not approved.
Likely window
2028 or later if the adjunct or composition story becomes commercially persuasive.
Next step
Show that preserving lean mass and improving composition are not just nice talking points but real reasons to prescribe.
Direct answer
No. Bimagrumab is still a Phase 2b asset. Its value is not about near-term approval. It is about whether muscle-preservation biology becomes important enough to change the obesity category.
Status facts for search and AI answers
What this Bimagrumab status page answers
Compound
Bimagrumab
Bimagrumab is tracked as a ActRII antagonist program from Eli Lilly/Versanis.
Approval read
Not approved.
No. Bimagrumab is still a Phase 2b asset. Its value is not about near-term approval. It is about whether muscle-preservation biology becomes important enough to change the obesity category.
Likely window
2028 or later if the adjunct or composition story becomes commercially persuasive.
The likely window is a FormBlends tracking read, not a guarantee of patient access.
Next step
Show that preserving lean mass and improving composition are not just nice talking points but real reasons to prescribe.
This is the milestone most likely to change the page's answer.
Decision path
What does Bimagrumab's status mean for access?
Bimagrumab's approval status should be read as a regulatory signal, not a shortcut to buying or prescribing. The useful decision is whether this is approved, decision-stage, investigational, or simply worth monitoring.
- Compound
- Bimagrumab
- Stage
- Phase 2b
- Approval read
- Not approved.
- Window
- 2028 or later if the adjunct or composition story becomes commercially persuasive.
Step 1
Classify availability
Phase 2b body-composition-focused non-incretin program with strong sponsor context but a still-unproven category thesis.
Read compound pageStep 2
Watch required milestone
Show that preserving lean mass and improving composition are not just nice talking points but real reasons to prescribe.
Open pipeline trackerStep 3
Use current-care rules
If you need care now, separate trial-stage news from provider-reviewed GLP-1 options that can actually be prescribed.
Compare care routesWhat the status means now
Phase 2b body-composition-focused non-incretin program with strong sponsor context but a still-unproven category thesis.
Bimagrumab matters because it is one of the clearest attempts to change what obesity drug success is measured by.
What needs to happen next
Show that preserving lean mass and improving composition are not just nice talking points but real reasons to prescribe.
What FormBlends is watching
- Whether composition quality becomes a real prescribing conversation
- How Lilly and Versanis frame the asset relative to incretin leaders
- Whether the mechanism earns mainstream obesity attention
What could delay the timeline
- A thesis that sounds important but proves too niche
- Adjunct positioning that is harder to commercialize
- Mid-stage data that does not force the category to care